3 results match your criteria: "1 School of Paediatrics and Child Health.[Affiliation]"
Article Synopsis
- NE activity is linked to lung damage in cystic fibrosis (CF) and disrupts normal airway epithelial maintenance, but its specific effects on young children with CF are not well understood.
- The study investigates how NE influences epithelial cell viability, inflammation, apoptosis, and repair in primary airway epithelial cells (pAEC) from both healthy and CF children, revealing that NE significantly reduces cell viability and disrupts repair processes.
- The harmful effects of NE on CF airway cells can be counteracted by the antiprotease alpha-1 antitrypsin (α1AT), suggesting potential therapeutic avenues for early CF treatment.
Rationale: Chest computed tomography (CT) is the gold standard for demonstrating cystic fibrosis (CF) airway disease. However, there are no standardized outcome measures appropriate for children younger than 6 years.
Objectives: We developed the Perth-Rotterdam Annotated Grid Morphometric Analysis for CF (PRAGMA-CF), a quantitative measure of airway disease, and compared it with the commonly used CF-CT scoring method.
Lung deposition of 99mTc-radiolabeled albuterol delivered through a pressurized metered dose inhaler and spacer with facemask or mouthpiece in children with asthma.
J Aerosol Med Pulm Drug Deliv
August 2014
1 School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia .
Background: Research on the use of a pressurized metered dose inhaler (pMDI) with spacer (pMDI/spacer) in children has indicated oral inhalation via the spacer mouthpiece is more efficient than the combination of oral and nasal inhalation that occurs when a pMDI/spacer is used with a facemask. Changes in pMDI formulations and developments in spacer and facemask designs have highlighted the need for new comparative studies of spacer use, particularly focusing on the age at which children can be taught to transition from use of a pMDI/spacer with facemask to use of the spacer mouthpiece.
Methods: Twelve children aged 3-5 years (7 males) with stable asthma were recruited.